RG
ACRS icon

Redmile Group’s Aclaris Therapeutics ACRS Stock Holding History

Redmile Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,320
Closed -$68K – 82
2019
Q1 		$68K Hold
11,320
– – ﹤0.01% 81
2018
Q4 		$84K Hold
11,320
– – ﹤0.01% 75
2018
Q3 		$164K Sell
11,320
-95,500
-89% -$1.64M 0.01% 81
2018
Q2 		$2.13M Hold
106,820
– – 0.07% 65
2018
Q1 		$1.87M Sell
106,820
-200
-0.2% -$4.24K 0.07% 57
2017
Q4 		$2.64M Buy
107,020
+6,060
+6% +$148K 0.11% 60
2017
Q3 		$2.61M Buy
100,960
+6,400
+7% +$172K 0.13% 56
2017
Q2 		$2.56M Buy
94,560
+3,860
+4% +$105K 0.16% 54
2017
Q1 		$2.71M Sell
90,700
-3,500
-4% -$101K 0.18% 54
2016
Q4 		$2.56M Buy
+94,200
New +$2.4M 0.22% 44

Other funds holding ACRS

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Redmile Group's ACRS Position: Q2 2019 in Review

Redmile Group sold out of Aclaris Therapeutics (ACRS) in Q2 2019, closing a stake of 11,320 shares — an estimated $68K sold.

Redmile Group first reported a position in ACRS in Q4 2016 and held it in 10 quarters. The position peaked at $2.71M in Q1 2017. 84 funds tracked by Wall St. Rank hold ACRS as of Q2 2019.

  • Redmile Group reported no remaining Aclaris Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Redmile Group sold 11,320 Aclaris Therapeutics shares in Q2 2019, an estimated $68K.
  • Redmile Group first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 10 quarters.
  • Redmile Group's Aclaris Therapeutics position peaked at $2.71M in Q1 2017.
  • 84 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2019.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.